• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Curevac N.V. (NQ: CVAC )

    2.535 -0.135 (-5.06%)
    Streaming Delayed Price Updated: 1:30 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Curevac N.V.

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
    - Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac's first-generation mRNA... 
    From CureVac
    Via AccessWire
    Topics Intellectual Property Regulatory Compliance
    Exposures COVID-19 Intellectual Property Legal
    Unusual Options Activity Insight: CureVac
    CureVac (NASDAQ:CVAC) shares experienced unusual options ... 
    Via Benzinga
    26 Stocks Moving in Thursday's Pre-Market Session
    Gainers Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares rose 34% to $5.48 in pre-market trading after dropping around 15% on Wednesday. Ensysce Biosciences recently appointed... 
    Via Benzinga
    Why CureVac Shares Are Trading Lower Today
    CureVac BV (NASDAQ:CVAC) shares are trading lower by 3.6% ... 
    Via Benzinga
    EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine
    EMA's human medicines committee has kicked off a rolling review of a COVID-19 vaccine from Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (... 
    Via Benzinga
    Exposures COVID-19
    Can CureVac Win Market Share With Only 48% Vaccine Efficacy?
    CureVac aims to become one of Europe's big suppliers. 
    Via The Motley Fool
    Unusual Options Activity Insight: CureVac
    On Wednesday, shares of CureVac (NASDAQ:CVAC) saw unusual options activity. After the option alert, the stock price moved down to $59.8. Sentiment: BEARISH Option Type: SWEEP... 
    Via Benzinga
    South Korea Negotiating With mRNA COVID-19 Vaccine Makers To Produce Up To 1B Doses: Reuters
    South Korea is reportedly in talks with mRNA vaccine makers, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), to produce COVID-19 shots in the... 
    Via Benzinga
    Exposures COVID-19
    Here's Why You Should Avoid CureVac Stock Like the Plague
    Funds will not be safe if invested in this coronavirus stock. 
    Via The Motley Fool
    Exposures COVID-19
    Is CureVac a Bargain Bet on mRNA Vaccine Technology?
    CureVac shares have slipped more than 20% on bad news. 
    Via The Motley Fool
    Topics Cannabis
    Exposures COVID-19 Cannabis
    The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week
    Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,... 
    Via Talk Markets
    Exposures COVID-19 Product Safety
    The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
    Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few... 
    Via Benzinga
    Exposures Product Safety
    Moderna and Pfizer May Benefit From This Rival's Bad News
    And it could equal billions of dollars for these vaccine leaders. 
    Via The Motley Fool
    Topics Cannabis
    Exposures COVID-19 Cannabis
    Can CureVac Recover After Its Vaccine Setback?
    Investors' dreams of a third strong mRNA vaccine may be over. 
    Via The Motley Fool
    Topics Cannabis
    Exposures COVID-19 Cannabis
    58 Biggest Movers From Yesterday
    Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share. Pop Culture Group Co., Ltd (... 
    Via Benzinga
    Topics Initial Public Offering
    Exposures Securities Market
    30 Stocks Moving In Thursday's Mid-Day Session
    Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 104.6% to $62.00. Pop Culture Group shares jumped 405% on Wednesday after the company priced its IPO at $6 per... 
    Via Benzinga
    Topics Initial Public Offering
    Exposures Securities Market
    Analyzing CureVac's Unusual Options Activity
    CureVac (NASDAQ:CVAC) shares experienced unusual options activity on Thursday. The stock price moved down to $68.53 following the option alert. Sentiment: BULLISH Option Type:... 
    Via Benzinga
    20 Stocks Moving in Thursday's Pre-Market Session
    Gainers Alterity Therapeutics Ltd (NASDAQ: ATHE) shares rose 64% to $2.14 in pre-market trading. Alterity Therapeutics recently said it received EU regulatory guidance for ATH434... 
    Via Benzinga
    The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
    Via Benzinga
    Exposures Product Safety
    A Peek Into The Markets: US Stock Futures Up Ahead Of Initial Jobless Claims Data
    Pre-open movers U.S. stock futures traded higher in early pre-market trade ahead of initial jobless claims data. The Dow Jones climbed over 200 points on Wednesday, while the S... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    CureVac Stock Drops After Final Results Confirm Its COVID-19 Vaccine Trails Rivals
    The German biotech company CureVac BV (NASDAQ: CVAC) announced on Wednesday after hours the final results of its late-stage COVID-19 vaccine trial showing 48%... 
    Via Benzinga
    Exposures COVID-19
    CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60
    - Unique pivotal study conducted in 10 countries in fast changing variant environment; 15 COVID-19 variant strains present for efficacy analysis; original strain almost completely absent - Statistical... 
    From CureVac
    Via AccessWire
    Topics Intellectual Property Regulatory Compliance
    Exposures COVID-19 Intellectual Property Legal
    CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)
    TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 30, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on... 
    From CureVac
    Via AccessWire
    Topics Intellectual Property Regulatory Compliance
    Exposures COVID-19 Intellectual Property Legal
    June’s Best and Worst Performing Russell 1,000 Stocks
    The month of June, the second quarter and the first half of 2021 are almost in the bag. 
    Via Talk Markets
    Without a Coronavirus Vaccine Of Its Own, Is There Any Hope For CureVac Stock?
    Things are looking bleak right now, but they might improve with enough time. 
    Via The Motley Fool
    Exposures COVID-19
    CureVac Announces Voting Results of General Meeting
    TÜBINGEN, GERMANY andBOSTON, MA / ACCESSWIRE / June 25, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on... 
    From CureVac
    Via AccessWire
    Topics Intellectual Property Regulatory Compliance
    Exposures COVID-19 Intellectual Property Legal
    CureVac Provides Supervisory Board Update
    TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 23, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on... 
    From CureVac
    Via AccessWire
    Topics Intellectual Property Regulatory Compliance
    Exposures COVID-19 Intellectual Property Legal
    Could CureVac Be a Millionaire-Maker Stock?
    CureVac's first COVID vaccine candidate disappointed investors. But a second one looks promising. 
    Via The Motley Fool
    Exposures COVID-19
    How Pfizer and Moderna Could Profit Big-Time From AstraZeneca's and CureVac's Challenges
    Bad news for AstraZeneca and CureVac should mean more good news for Pfizer and Moderna. 
    Via The Motley Fool
    Exposures COVID-19
    Europe Purchases Additional 150M Doses Of Moderna COVID-19 Vaccine
    The European Union has decided to take up an option under a supply contract with Moderna Inc (NASDAQ: MRNA) that allows the bloc to order 150 million... 
    Via Benzinga
    Exposures COVID-19
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.